Drugs / AIDSVAX® B/E
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03618056 | Dec 2018 → Jul 2020 | HIV infectious disease, systemic lupus erythematosus | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AIDSVAX B/E | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03618056 ↗ |
| Modality | Vaccine | “HIV gp120 protein vaccine” NCT03618056 ↗ |
| Route | Intramuscular | “Administered by intramuscular injection” NCT03618056 ↗ |